Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 58Carcinoma, Hepatocellular 28Breast Neoplasms 26Small Cell Lung Carcinoma 20Lung Neoplasms 20Triple Negative Breast Neoplasms 18Urinary Bladder Neoplasms 17Neoplasms 16Carcinoma, Transitional Cell 16Neoplasm Metastasis 15Melanoma 15Colorectal Neoplasms 15Uterine Cervical Neoplasms 11Carcinoma, Renal Cell 10Stomach Neoplasms 7Recurrence 7Head and Neck Neoplasms 7Prostatic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Mesothelioma, Malignant 5Liver Neoplasms 5Carcinoma, Squamous Cell 5Ovarian Neoplasms 4Esophageal Neoplasms 4Carcinoma, Merkel Cell 4Biliary Tract Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Thoracic Neoplasms 3

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Safety Issues × atezolizumab × Clear all
NCT03620435 2018-08-13

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 2 Unknown
25 enrolled

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon âš¡